Difference between revisions of "Alpha-2 plasmin inhibitor (FXIIIa)"
m |
m |
||
| Line 1: | Line 1: | ||
{| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | {| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | ||
! {{infobox header}}| '''{{PAGENAME}}''' | ! {{infobox header}}| '''{{PAGENAME}}''' | ||
| − | |||
| − | |||
|- | |- | ||
| Substrate peptide name | | Substrate peptide name | ||
Revision as of 14:13, 7 January 2008
| Template:Infobox header| Alpha-2 plasmin inhibitor (FXIIIa) | |
|---|---|
| Substrate peptide name | Alpha-2 plasmin inhibitor |
| Synonyms | Alpha-2-antiplasmin |
| Determination type | In vitro |
| Source | Homo sapiens |
| Subcellular localization | Extracellular; plasma |
| Swissprot ID | P08697 |
| Reactive glutamines | Q2 |
| Reactive lysines | - |
| Substrate sequence | NQEEVSP |
| Structure | No available crystal structure |
| Surface accessibility | |
| Disorder prediction | IUPred |
| Reference | PMID:10958788 |
| Notes | 4 of 35 Q residues were labeled with the following
reactivities: Q2 > Q21 > Q419 > Q447 |
| Template:Infobox header | |
